Infants, colic and constipation: how can pharmacists help? - Certificate of Completion

Duration

1 hr

Profession

Pharmacy

# of Credits

1.0

Accreditation

Certificate of Completion

Expiry Date

2020-12-14

According to the World Health Organization (WHO), colic and functional constipation are among the three most common gastrointestinal disorders, affecting 20% and 15% of infants respectively. These disorders are hypothesised to incur a significant financial burden, trigger doctor consultations and hospital visits, and decrease the quality of life of infants and their families.

There is growing evidence that common gut disorders that present during infancy are accompanied by gut dysbiosis and are mediated by gut flora. The incidence of gastrointestinal intolerance is lower among infants who receive breastmilk, however, many mothers cease breastfeeding early and introduce formula into their infants’ diets, often without consulting a health professional.

While FGID are generally thought to be benign and self-resolving, community pharmacists may need to focus on educating parents and caregivers on identifying signs and symptoms, as well as appropriate management of these disorders, while concurrently providing support and reassurance.

This interactive online learning activity is valued at 1 Hour(s) of continuing education.

Greg Kyle
BPharm MClinPharm PhD MPS
Professor of Pharmacy (Head of Discipline)
Director International Engagement and Recruitment,
School of Clinical Sciences
Queensland University of Technology

Vincent Ho
MBBS BSc(Med) MMed FRACP PhD
Gastroenterologist, Campbelltown Hospital, Sydney
Senior Lecturer, School of Medicine,
Western Sydney University

Une fois le programme terminé, les participants seront en mesure de :

  1. Reconnaître le rôle du microbiote intestinal dans la santé gastro-intestinale et globale.
  2. Définir l’importance des effets potentiels des antibiotiques sur le microbiote intestinal du patient.
  3. Décrire l’étiologie et les risques de diarrhée associée aux antibiotiques (DAA) et de diarrhée associée au Clostridium difficile (DACD) et le rôle des probiotiques dans la prévention de la diarrhée associée aux antibiotiques.
  4. Évaluer les études scientifiques en cours soutenant les propriétés uniques et l’efficacité clinique d’une formule de probiotiques pour prévenir la DAA et la DACD.
  5. Recommander un probiotique spécifique en tant que thérapie préventive contre la DAA et la DACD.


Related Courses